Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 1:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 66 matching trials from the live ClinicalTrials.gov search.
Conditions
Bullous Keratopathy, Corneal Erosion, Entropion, Corneal Edema, Corneal Dystrophy
Interventions
Lotrafilcon A contact lenses, Balafilcon A contact lenses
Device
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Delray Beach, Florida • St Louis, Missouri • Fort Worth, Texas
Completed Phase 2 Interventional Results available

Long-Term Study of Nitisinone to Treat Alkaptonuria

NCT00107783
Conditions
Alkaptonuria
Interventions
Nitisinone (NTBC)
Drug
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
30 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Keratoconus, Ectasia, Crosslinking, Fuchs' Endothelial Dystrophy
Interventions
Brillouin imaging
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
20 Years to 75 Years
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Cataract, Glaucoma, Retinitis Pigmentosa, Macular Degeneration, Strabismus
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Fuchs Endothelial Corneal Dystrophy
Interventions
STN1010904 ophthalmic suspension 0.03% BID, STN1010904 ophthalmic suspension 0.1% BID, Placebo (Vehicle) BID
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
30 Years to 75 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
11
States / cities
Los Angeles, California • Indianapolis, Indiana • Baltimore, Maryland + 8 more
Conditions
Corneal Endothelial Decompensation, Fuchs' Endothelial Dystrophy
Interventions
Descemet membrane endothelial keratoplasty
Procedure
Lead sponsor
Case Western Reserve University
Other
Eligibility
30 Years to 90 Years
Enrollment
1,097 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Indianapolis, Indiana • Grand Rapids, Michigan
Completed Phase 4 Interventional Accepts healthy volunteers

The Evaluation of Balanced Salt Solution During Cataract Surgery

NCT05853978
Conditions
Fuchs Dystrophy, Cataract
Interventions
BSS Plus, BSS
Drug
Lead sponsor
Adam Fedyk, MD, FACS
Other
Eligibility
22 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Town and Country, Missouri
Conditions
Fuchs Dystrophy, Corneal Edema
Interventions
Corneal transplantation
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Recruiting No phase listed Observational Accepts healthy volunteers

OCT in Diagnosis of Irregular Corneas

NCT03504800
Conditions
Keratoconus, Corneal Opacity, Corneal Dystrophy
Interventions
Optical Coherence Tomography
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
14 Years to 85 Years
Enrollment
445 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2031
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Fuchs' Endothelial Dystrophy
Interventions
Amphotericin B
Drug
Lead sponsor
Cornea Research Foundation of America
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Fuchs Endothelial Corneal Dystrophy
Interventions
Ripasudil, Placebo
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
21
States / cities
Los Angeles, California • Palo Alto, California • Sacramento, California + 17 more
Conditions
Fuchs' Endothelial Dystrophy, Fuchs Dystrophy, Fuchs
Interventions
TTHX1114(NM141)
Drug
Lead sponsor
Trefoil Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
11
States / cities
Long Beach, California • Petaluma, California • Deerfield Beach, Florida + 8 more
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

Assessment of Corneal Endothelial Function Following Hypoxic Stress

NCT04175938
Conditions
Fuchs' Endothelial Corneal Dystrophy
Interventions
Wearing of contact lens
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Fuchs, Fuchs Dystrophy, Fuchs' Endothelial Dystrophy
Interventions
Ripasudil, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
8
States / cities
Palo Alto, California • Sacramento, California • Palm Beach Gardens, Florida + 3 more
Conditions
Fuchs' Corneal Dystrophy, Cataract
Interventions
Descemetorhexis
Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Fuchs' Endothelial Dystrophy, Bullous Keratopathy
Interventions
Netarsudil, Placebo
Drug
Lead sponsor
Cornea Research Foundation of America
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Completed Phase 1Phase 2 Interventional Results available

A Phase 1/ Phase 2 Study of TTHX1114(NM141)

NCT04520321
Conditions
Corneal Endothelial Dystrophy, Fuchs Endothelial Corneal Dystrophy, Pseudophakic Bullous Keratopathy, Endothelial Dysfunction
Interventions
TTHX1114(NM141), Vehicle (placebo)
Drug · Other
Lead sponsor
Trefoil Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
8
States / cities
Petaluma, California • Jacksonville, Florida • Hoffman Estates, Illinois + 5 more
Conditions
Corneal Opacity
Interventions
OCT-guided laser phototherapeutic keratectomy
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Inherited Ophthalmic Diseases, Hypopigmentation Disorder, Corneal Dystrophy, Blue-cone Monochromacy, Best Disease, Aniridia, Albinism
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
1 Day to 120 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2054
U.S. locations
2
States / cities
Bethesda, Maryland
Conditions
Hereditary Corneal Dystrophy, Corneal Abnormality, Corneal Dystrophies, Corneal Dystrophies, Hereditary
Interventions
GEB-101 Injection
Genetic
Lead sponsor
GenEditBio Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Completed No phase listed Observational Accepts healthy volunteers

DISCOVER Study: Microscope-integrated Intraoperative OCT Study

NCT02423213
Conditions
Retinal Diseases, Fuchs Endothelial Dystrophy, Macular Hole, Epiretinal Membrane, Retinal Detachment
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
2,911 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Sjögren Syndrome, Dry Eye
Interventions
observational study
Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
15
States / cities
Bakersfield, California • Aurora, Colorado • Jacksonville, Florida + 12 more
Conditions
Cystinosis
Interventions
Cysteamine
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
2 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1986 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Fuchs Endothelial Corneal Dystrophy
Interventions
N-acetyl cysteine (NAC) 10% solution, N-acetyl cysteine (NAC) 20% solution, Visine Dry Eye Relief eye drops
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
21 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts